Related Experiment Video
Updated: Jul 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Severe asthma and the omalizumab option
Christopher Wt Miller1, Narayanaswamy Krishnaswamy, Chambless Johnston
1Division of Allergy and Clinical Immunology, Quillen College of Medicine, Johnson City, TN, USA. KRISHNAS@mail.etsu.edu.
Omalizumab, a new treatment for chronic asthma, targets immunoglobulin E (IgE) to reduce exacerbations and improve quality of life. While effective, potential adverse effects like anaphylaxis require careful patient selection and monitoring.
Area of Science:
- Allergy and Immunology
- Pulmonology
- Pharmacology
Background:
- Asthma is a growing global health concern, characterized by chronic airway inflammation often driven by immunoglobulin E (IgE).
- Current asthma treatments, while available, do not offer a cure and can lead to exacerbations, hospitalizations, and medication side effects.
- Severe asthma can be debilitating and even fatal, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the role of omalizumab, a humanized monoclonal antibody targeting IgE, in managing chronic asthma.
- To evaluate the efficacy and safety of omalizumab, including its steroid-sparing potential and impact on quality of life.
- To discuss the current indications and considerations for omalizumab use in allergic asthma.
Main Methods:
- Review of existing literature on omalizumab's mechanism of action, clinical benefits, and adverse effects in asthma.
- Analysis of studies examining omalizumab's impact on exacerbations, pulmonary function, quality of life, and steroid dependence.
- Consideration of FDA recommendations and current asthma guidelines regarding omalizumab's use.
Main Results:
- Omalizumab effectively reduces asthma exacerbations and demonstrates a steroid-sparing effect, potentially decreasing glucocorticoid-related adverse effects.
- Patients treated with omalizumab report improvements in quality of life measures, though effects on pulmonary function may be modest.
- Omalizumab is indicated for moderate to severe persistent allergic asthma (steps 5 and 6) and has shown potential in other allergic conditions, though data is limited.
Conclusions:
- Omalizumab is a valuable therapeutic option for selected patients with moderate to severe allergic asthma, offering benefits beyond exacerbation control.
- Careful patient selection and monitoring are crucial due to potential adverse effects, including the rare risk of anaphylaxis.
- Further research is needed to clarify omalizumab's role in other allergic diseases and its long-term impact.
More Related Videos
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-IV: Nursing Management
First, in...
